Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Prices $175M Common Stock Offering

NEW YORK – CareDx said on Wednesday that it has priced an underwritten public offering of 1,923,077 shares of its common stock, at $91 per share.

The transplant diagnostics company expects gross proceeds from the offering of $175 million. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 288,461 additional shares. In a filing with the US Securities and Exchange Commission, CareDx estimated that the net proceeds from the offering will be approximately $164.1 million, or about $188.8 million if the underwriters exercise their option to purchase the additional shares.

The company said it intends to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on or about Jan. 25.

Goldman Sachs and Jefferies are acting as joint book-running managers for the offering. Raymond James, BTIG, Craig-Hallum Capital Group, and HC Wainwright are acting as co-managers.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.